Hot Topics · Cross-industry
MedTech Reimbursement Shift
CMS and private payer coverage decisions changing device demand.
AI-generated · informational only · not investment advice · verify before relying.
01 · The lede
Intelligence brief
SeventhBiz Intelligence
Refreshed 3h agoReimbursement has shifted from a predictable, stable backdrop to an active constraint on revenue recognition and market access across medtech and pharma. The IRA Medicare price negotiation program is now operational across multiple drug classes (Januvia, Eliquis, Biktarvy confirmed; Keytruda next), creating stacked price reductions of 38% or more alongside parallel mechanisms: the GENEROUS Model (all 50 states plus DC enrolled in Medicaid rebate benchmarking), 340B pilot program restructuring (effective January 2027), MFN government agreements, and MAC pathway expansions for device coverage.…
The full brief is part of the subscription
03 · Companies
Companies engaging with this topic
Tracked companies with an on-record signal on MedTech Reimbursement Shift this cycle.
06 · Evidence
Recent mentions
Preview“the teams have been hard at work at increasing access on a national basis to get access to their product on a payer-by-payer basis”
Q&A — Michael Polark (Wolfe Research) exchange with Quentin Blackford
“In June 2026, the LCDs were finalized. Among other clarifications, the final LCDs eliminated the requirement to apply attended monitoring to Holter monitors.”
Risk Factors — Reimbursement & Payer Coverage
“We think the price is going to drop 50% on that 3% of sales, and all of that will come out of gross margin.”
Q&A — Jon Block (Stifel) 2027 margin question
Unlock MedTech Reimbursement Shift
The full intelligence brief, how the language shifted quarter over quarter, the bear case, and every company mention — verbatim and source-cited.